Table 2 Comparison of the clinicopathological features in NEN and IBC-NST patients.
From: Clinical and genomic analyses of neuroendocrine neoplasms of the breast
Features | NEN (N = 17) | NET (N = 6) | NEC (N = 11) | IBC-NST (N = 755) | P1 NET vs. NEC | P2 NEN vs. IBC-NST |
|---|---|---|---|---|---|---|
Age | ||||||
Mean | 50 ± 12.9 | 52.3 ± 13.8 | 48.7 ± 12.9 | 47.6 ± 9.9 | 0.256 | <0.001 |
≤50 y | 9 (52.9) | 3 (50.0) | 6 (54.5) | 453 (60.0) | 1.000 | 0.620 |
>50 y | 8 (47.1) | 3 (50.0) | 5 (45.5) | 302 (40.0) | ||
Gender | ||||||
Female | 17 (100) | 6 (100.0) | 11 (100.0) | 753 (99.7) | - | 1.000 |
Male | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.3) | ||
Menstruation | ||||||
Prem | 10 (58.8) | 4 (66.7) | 6 (54.5) | 474 (62.3) | 1.000 | 0.802 |
Postm | 7 (41.2) | 2 (33.3) | 5 (45.5) | 281 (37.2) | ||
Laterality | ||||||
Left | 6 (35.3) | 1 (16.7) | 5 (45.5) | 394 (52.2) | 0.333 | 0.221 |
Right | 11 (64.7) | 5 (83.3) | 6 (54.5) | 361 (47.8) | ||
cT | ||||||
1 | 4 (23.5) | 3 (50.0) | 1 (9.1) | 49 (6.5) | ||
2 | 13 (76.5) | 3 (50.0) | 10 (90.9) | 322 (42.6) | ||
3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 121 (16.0) | 0.099 | <0.001 |
4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 250 (33.1) | ||
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (1.7) | ||
cN | ||||||
0 | 9 (52.9) | 5 (83.3) | 4 (36.4) | 61 (8.1) | ||
1 | 2 (11.8) | 0 (0.0) | 2 (18.2) | 281 (37.2) | ||
2 | 2 (11.8) | 0 (0.0) | 2 (18.2) | 148 (19.6) | 0.263 | <0.001 |
3 | 4 (23.5) | 1 (16.7) | 3 (27.3) | 200 (26.5) | ||
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 65 (8.6) | ||
TNM stage | ||||||
I + II | 12 (70.6) | 5 (83.3) | 7 (63.6) | 212 (28.1) | ||
III + IV | 5 (29.4) | 1 (16.7) | 4 (36.4) | 522 (69.1) | 0.600 | 0.001 |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 21 (2.8) | ||
pT | ||||||
1 | 4 (23.5) | 3 (50.0) | 1 (9.1) | 327 (43.3) | ||
2 | 13 (76.5) | 3 (50.0) | 10 (90.9) | 320 (42.4) | ||
3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 53 (7.0) | 0.099 | 0.069 |
4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 35 (4.6) | ||
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 20 (2.6) | ||
pN | ||||||
0 | 10 (58.8) | 5 (83.3) | 5 (45.5) | 197 (26.1) | ||
1 | 2 (11.8) | 0 (0.0) | 2 (18.2) | 275 (36.4) | ||
2 | 2 (11.8) | 0 (0.0) | 2 (18.2) | 161 (21.3) | 0.371 | 0.017 |
3 | 3 (17.6) | 1 (16.7) | 2 (18.2) | 122 (16.2) | ||
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (1.3) | ||
NG | ||||||
1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 21 (2.8) | <0.001 | 0.175 |
2 | 6 (35.3) | 6 (100.0) | 0 (0.0) | 382 (50.6) | ||
3 | 11 (64.7) | 0 (0.0) | 11 (100.0) | 300 (39.7) | ||
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 52 (6.9) | ||
LVI | ||||||
Yes | 12 (70.6) | 0 (0.0) | 5 (45.5) | 138 (18.3) | 0.102 | 0.348 |
No | 5 (29.4) | 6 (100.0) | 6 (54.5) | 578 (76.6) | ||
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 39 (5.2) | ||
ER | ||||||
Negative | 2 (11.8) | 1 (16.7) | 1 (9.1) | 201 (26.6) | 1.000 | 0.264 |
Positive | 15 (88.2) | 5 (83.3) | 10 (90.9) | 554 (73.4) | ||
PR | ||||||
Negative | 1 (5.9) | 0 (0.0) | 1 (9.1) | 239 (31.7) | ||
Positive | 16 (94.1) | 6 (100.0) | 10 (90.9) | 515 (68.2) | 1.000 | 0.030 |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | ||
HER2 | ||||||
Negative | 12 (70.6) | 6 (100.0) | 6 (54.5) | 596 (78.9) | 0.102 | 0.378 |
Positive | 5 (29.4) | 0 (0.0) | 5 (45.5) | 159 (21.1) | ||
Ki67 | ||||||
≤20% | 3 (17.6) | 4 (66.7) | 0 (0.0) | 220 (29.1) | ||
>20% | 14 (82.4) | 2 (33.3) | 11 (100.0) | 496 (65.7) | 0.029 | 0.776 |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 39 (5.2) | ||
Subtypes | ||||||
HR + HER2- | 12 (70.6) | 6 (100.0) | 6 (54.5) | 479 (63.4) | 0.145 | 0.330 |
HR + HER2 + | 4 (23.5) | 0 (0.0) | 4 (36.4) | 118 (15.6) | ||
HR-HER2 + | 1 (5.9) | 0 (0.0) | 1 (9.1) | 41 (5.4) | ||
HR-HER2- | 0 (0.0) | 0 (0.0) | 0 (0.0) | 117 (15.5) | ||
Pathways | ||||||
PI3K | 4 (23.5) | 3 (50.0%) | 2 (18.2) | – | <0.001 | – |
Chrom remod | 8 (47.1) | 2 (33.3) | 6 (54.5) | – | 0.620 | – |
MAPK | 7 (41.2) | 5 (83.3) | 2 (18.2) | – | 0.035 | – |
RB | 5 (29.4) | 2 (33.3) | 3 (27.3) | – | 1.000 | – |
p53 | 2 (11.8) | 0 (0.0) | 2 (18.2) | – | 0.515 | – |
RTK | 5 (29.4) | 3 (50.0) | 2 (18.2) | – | 0.280 | – |
MYC | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | - | – |
